anayamalik, Author at European Medical Journal - Page 77 of 97

Lessons from HIV/AIDS and COVID-19

The global challenges posed by HIV/AIDS and COVID-19 provide critical insights for managing future infectious disease outbreaks, according to a recent study by Anthony S Fauci and Gregory K Folkers.

Thin Melanomas: A Critical 0.8 mm Threshold

A recent cohort study involving 144,447 participants has found a crucial threshold in melanoma risk for tumors with a Breslow thickness between 0.8 and 1.0 mm.

Deep Learning Tool Predicts Immunotherapy Efficacy in Lung Cancer

A novel deep learning-based radiomic biomarker could significantly enhance prediction of response to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC).

What Do Migraine And Gastrointestinal Disorders Have In Common?

A study has uncovered significant genetic overlap between migraine and several gastrointestinal (GI) disorders, suggesting shared underlying neurologic mechanisms despite diverse etiologies.

COMET Trial Explores DCIS Treatment Dilemma: SABCS 2024

Patients with low-risk ductal carcinoma in situ (DCIS) who chose active monitoring over immediate surgery reported similar quality-of-life outcomes, according to findings from the COMET trial presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Data, Risks, and Mortality Rates Of Fungal Infections After HSCT

A recent multicenter study in China provides critical insights into the persistent threat of invasive fungal disease (IFD) among patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

RBC Transfusions: New Guidelines for ICU Care

New evidence-based guidelines for red blood cell (RBC) transfusions in critically ill patients have been released, offering critical care practitioners a roadmap to optimize patient outcomes.

Risk-Reducing Surgery for BRCA Carriers: SABCS 2024

Risk-reducing surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved survival outcomes in BRCA-mutation carriers diagnosed with breast cancer at or before age 40, according to a study presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

COMET Trial Suggests Active Monitoring for Low-Risk DCIS: SABCS 2024

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

Melanoma Survivors Face 57% Increased Risk of Malignancies

Survivors of cutaneous melanoma (CM) face a 57% increased risk of developing second primary malignancies (SPMs) compared to the general population, according to groundbreaking research from a recent analysis of SEER database data spanning two decades.